AbbVie has touted Skyrizi as a key pillar of its future beyond Humira, and on Thursday, the company read out results suggesting the IL-23 inhibitor succeeded as a maintenance therapy for ulcerative colitis.
The pharma giant reported that continued treatment with Skyrizi (risankizumab) led to a “significantly higher” rate of clinical remission from ulcerative colitis compared to patients who received only induction therapy. The topline results come just a few months after AbbVie announced that its Phase III induction study met the primary and all secondary endpoints in adults with moderately to severely active ulcerative colitis.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters